Elicio Therapeutics Inc
Elicio Therapeutics Inc (ELTX) Implied Volatility Current
ELTX implied volatility is 235%. IV Rank is 56%, placing current premiums in the middle of their 52-week range.
Read more
Tracking ELTX implied volatility helps you identify when options premiums on Elicio Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Elicio Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when ELTX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Elicio Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ELTX, tracking metrics like ELTX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ELTX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.
The company is headquartered in Boston, Massachusetts.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ELTX implied volatility sits today versus where it has been. Our scanner ranks Elicio Therapeutics Inc implied volatility against its historical range, surfaces extremes in ELTX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Elicio Therapeutics Inc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is slightly elevated - premiums are richer, leaning toward sellers.
As of September 18, 2026
Trade options with IV on your side
Track ELTX IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→